
## Youngmee Jee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/176744/publications.pdf Version: 2024-02-01



YOUNCMEE LEE

#	Article	IF	CITATIONS
1	Outbreak of Measles in the Republic of Korea, 2007: Importance of Nosocomial Transmission. Journal of Infectious Diseases, 2011, 204, S483-S490.	4.0	49
2	First Imported Case of Zika Virus Infection into Korea. Journal of Korean Medical Science, 2016, 31, 1173.	2.5	32
3	Measles Elimination Activities in the Western Pacific Region: Experience from the Republic of Korea. Journal of Korean Medical Science, 2015, 30, S115.	2.5	28
4	Progress and Challenges for Measles Elimination by 2012 in the Western Pacific Region. Journal of Infectious Diseases, 2011, 204, S439-S446.	4.0	24
5	Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. Journal of Infectious Diseases, 2022, 225, 777-784.	4.0	21
6	Prediction of Residual Immunity to Smallpox, by Means of an Intradermal Skin Test with Inactivated Vaccinia Virus. Journal of Infectious Diseases, 2006, 194, 377-384.	4.0	17
7	Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines. Immune Network, 2021, 21, e29.	3.6	14
8	Status of HPV vaccination among HPV-infected women aged 20–60 years with abnormal cervical cytology in South Korea: a multicenter, retrospective study. Journal of Gynecologic Oncology, 2020, 31, e4.	2.2	8
9	Correlation between Reactogenicity and Immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccination. Immune Network, 2021, 21, e41.	3.6	8
10	Report of the Korean Society of Infectious Diseases Roundtable Discussion on Responses to the Measles Outbreaks in Korea in 2019. Infection and Chemotherapy, 2021, 53, 405.	2.3	7
11	Epidemiology and Clinical Characteristics of Zika Virus Infections Imported into Korea from March to October 2016. Journal of Korean Medical Science, 2017, 32, 1440.	2.5	4
12	Immune responses and reactogenicity after ChAdOx1 in individuals with past SARS-CoV-2 infection and those without. Journal of Infection, 2021, , .	3.3	3
13	COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER). Vaccine, 2021, 39, 2504-2505.	3.8	1
14	Breakthrough infections and waning immune responses with ChAdOx1 nCoVâ€19 or mRNA vaccine in healthcare workers. Clinical and Translational Medicine, 2022, 12, e804.	4.0	1